PCR testing company Vela Diagnostics reported on Tuesday the receipt of the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the ViroKey SARS-CoV-2 RT-PCR Test v2.0 to detect SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs.
Vela Diagnostics said its automated probe-based reverse transcription PCR test detects SARS-CoV-2, the coronavirus responsible for COVID-19. Laboratories in the US certified under the Clinical Laboratory Improvement Amendments can use the test for COVID-19 detection.
According to the company, the ViroKey SARS-CoV-2 RT-PCR Test v2.0 is an automated probe-based reverse transcription PCR test optimized for a workflow consisting of its Sentosa SX101 and the Sentosa SA201 instrument (or ABI 7500 Fast Dx). The automated test enables high throughput testing of up to 46 samples in a single run, with reduced hands-on time.
In addition, the company's ViroKey SARS-CoV-2 RT-PCR Test v2.0 has received the CE mark and Provisional Authorisation from the Singapore Health Sciences Authority.
US WorldMeds acquires Orbus Therapeutics
Enhertu wins EU approval for HER2-positive early breast cancer treatment
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
Solventum's combined use of Restrata Matrix and Solventum VAC Therapy receives FDA 510(k) clearance
Viatris' RYZUMVI receives US FDA Approval to treat presbyopia
Omeros receives negative EU opinion on narsoplimab after re-examination
Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia